This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.
Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced that its common shares have been approved for electronic clearing and settlement through the Depository Trust Company, a move expected to simplify trading for U.S. investors and enhance liquidity of the company’s shares. CEO Louis Dron said DTC eligibility improves access for U.S. investors and brokerage firms by enabling more efficient electronic clearing and settlement.
The company also announced it has engaged InvestorBrandNetwork to provide market awareness, corporate communications and digital media services, including editorial coverage, newsletter distribution, social media support and podcast syndication through Sept. 30, 2026, or until the allocated budget is exhausted. Redwood will pay IBN an aggregate cash fee of $114,000 for the services, with no securities issued as compensation.
To view the full press release, visit https://ibn.fm/t81xB
About Redwood AI Corp.
Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The Company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI’s platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications.
For more information go to https://redwoodai.com/
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
